Hunter to merge with Probiomics as it seeks partner for Phase II COPD vaccine
This article was originally published in Scrip
Executive Summary
Public unlisted Australian drug development company Hunter Immunology is recommending that its shareholders accept the takeover offer from listed biotech firm Probiomics.